5-(叔丁基）-3-氯甲基-1，2，4-恶二唑 | 175205-41-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(叔丁基）-3-氯甲基-1，2，4-恶二唑
• 中文别名: 5-(叔丁基)-3-氯甲基-1,2,4-噁二唑；5-(叔丁基)-3-氯甲基-1,2,4-恶二唑；5-(叔丁基)-3-氯甲基-1，2，4-恶二唑
• 英文名称: 5-tert-butyl-3-chloromethyl-1,2,4-oxadiazole
• 英文别名: 3-(chloromethyl)-5-(1,1-dimethylethyl)-1,2,4-oxadiazole；3-(chloromethyl)-5-tert-butyl-1,2,4-oxadiazole；5-t-butyl-3-(chloromethyl)-1,2,4-oxadiazole；5-tert-butyl-3-(chloromethyl)-1,2,4-oxadiazol；5-(Tert-Butyl)-3-(Chloromethyl)-1,2,4-Oxadiazole；5-tert-butyl-3-(chloromethyl)-1,2,4-oxadiazole
• CAS: 175205-41-1
• 化学式: C₇H₁₁ClN₂O
• mdl: MFCD00068196
• 分子量: 174.63
• InChiKey: AIVSLDAXUIRICJ-UHFFFAOYSA-N

物化性质

• 沸点：
  95 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  38.9
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38

SDS

Name:	5-(tert-Butyl)-3-(chloromethyl)-1 2 4-oxadiazole 95+% Material Safety Data Sheet
Synonym:
CAS:	175205-41-1

Section 1 - Chemical Product MSDS Name:5-(tert-Butyl)-3-(chloromethyl)-1 2 4-oxadiazole 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175205-41-1	5-(tert-Butyl)-3-(chloromethyl)-1,2,4-	95+%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175205-41-1: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 85 deg C @7.8mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature: Not available.
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H11ClN2O
Molecular Weight: 175

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175205-41-1 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-(tert-Butyl)-3-(chloromethyl)-1,2,4-oxadiazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, N.O.S.*
Hazard Class: 8
UN Number: 1760
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, N.O.S.
Hazard Class: 8
UN Number: 1760
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, N.O.S.
Hazard Class: 8
UN Number: 1760
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 175205-41-1: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175205-41-1 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175205-41-1 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(叔丁基）-3-氯甲基-1，2，4-恶二唑 生成 (R)-N-(3-((5-tert-butyl-1,2,4-oxadiazol-3-yl)methoxy)-4-chlorobenzyl)-1-(3-chlorophenyl)ethanamine
  参考文献：
  名称：

  Calcium receptor modulating agents

  摘要：

  本发明一般涉及公式I所代表的化合物，包括含有这些化合物的药物组合物以及治疗与钙感受受体功能相关的疾病或紊乱的方法。该发明还涉及制备这些化合物的方法以及在这些过程中有用的中间体。

  公开号：

  US20080221101A1
• 作为产物：
  描述：

  2-氯乙酰胺肟 、 三甲基乙酰氯 在 三乙胺 作用下， 以 DMF (N,N-dimethyl-formamide) 为溶剂， 反应 6.0h， 生成 5-(叔丁基）-3-氯甲基-1，2，4-恶二唑
  参考文献：
  名称：

  [EN] MALONONITRILE COMPOUND AS PESTICIDES
  [FR] COMPOSES DE MALONONITRILE UTILISABLES COMME PESTICIDES

  摘要：

  本发明提供了一种由式(I)表示的马隆二腈化合物：其中X1、X2、X3和X4中的任意一个是CR100，其中R100是由式表示的基团：X1、X2、X3和X4中的另外三个分别表示氮或CR5，前提是X1、X2、X3和X4中的1至3个表示氮，Z表示氧、硫或NR6，具有杀虫活性。

  公开号：

  WO2005068432A1

文献信息

• NOVEL DIHYDROPYRIMIDINOISOQUINOLINONES AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF INFLAMMATORY DISORDERS.
  申请人：GALAPAGOS NV

  公开号：US20130165437A1

  公开（公告）日：2013-06-27

  A compound according to Formula Ia: wherein L 1 , G, and R 1 are as described herein. The present invention relates to novel compounds according to Formula I that antagonize GPR84, a G-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (IBD), rheumatoid arthritis, vasculitis, lung diseases (e.g. chronic obstructive pulmonary disease (COPD) and lung interstitial diseases (e.g. idiopathic pulmonary fibrosis (IPF))), neuroinflammatory conditions, infectious diseases, autoimmune diseases, endocrine and/or metabolic diseases, and/or diseases involving impairment of immune cell functions by administering a compound of the invention.

  根据以下公式Ia的化合物： 其中L1、G和R1如本文所述。 本发明涉及根据公式I的新化合物，这些化合物对抗GPR84，G蛋白偶联受体，该受体参与炎症病症，以及这些新化合物的生产方法，包含这些化合物的药物组合物，以及通过给予本发明的化合物来预防和/或治疗炎症病症（例如炎症性肠病（IBD）、类风湿关节炎、血管炎、肺部疾病（例如慢性阻塞性肺病（COPD）和肺间质疾病（例如特发性肺纤维化（IPF）））、神经炎症病症、传染病、自身免疫疾病、内分泌和/或代谢疾病，以及/或通过给予本发明的化合物导致免疫细胞功能受损的疾病。
• [DE] DIBENZOXAZEPINE<br/>[EN] DIBENZOXAZEPINE<br/>[FR] DIBENZOXAZEPINES
  申请人：BAYER HEALTHCARE AG

  公开号：WO2004033437A1

  公开（公告）日：2004-04-22

  Die vorliegende Erfindung betrifft Verbindungen, Verfahren zur ihrer Herstellung, sie umfassende pharmazeutische Zusammensetzungen sowie ihre Verwendung bei der Behandlung und/oder Prophylaxe von Erkrankungen bei Menschen oder Tieren, insbesondere von Herz-Kreislauf-Erkrankungen, z. B. von Atherosklerose.

  本发明涉及化合物、其制备方法、包括它们的药物组合物以及它们在治疗和/或预防人类或动物疾病，特别是心血管疾病，例如动脉粥样硬化方面的用途。
• Substituted phenyl farnesyltransferase inhibitors
  申请人：——

  公开号：US20020019527A1

  公开（公告）日：2002-02-14

  Compounds of formula (I) 1 or pharmaceutically acceptable salts thereof, inhibit farnesyltransferase. Methods for making the compounds, pharmaceutical compositions containing the compounds, and methods of treatment using the compounds are disclosed.

  式(I)的化合物或其药学上可接受的盐，抑制法尼基转移酶。公开了制备这些化合物的方法，含有这些化合物的药物组合物，以及使用这些化合物进行治疗的方法。
• Alpha-helical mimetics
  申请人：Lessene Guillaume Laurent

  公开号：US20080153802A1

  公开（公告）日：2008-06-26

  Benzoyl urea derivatives that are alpha helical peptides mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting-moieties, and their use in the regulation of cell death are disclosed. The benzoyl urea derivatives are capable of binding to and neutralizing pro-survival Bcl-2 proteins. Use of benzoyl urea derivatives in the treatment and/or prophylaxis of diseases or conditions associated with deregulation of cell death are also described.

  公开了模拟α螺旋肽的苯甲酰脲衍生物，这些衍生物模拟BH3-仅蛋白，含有它们的组合物，它们与细胞靶向基团的结合，以及它们在调节细胞死亡中的用途。苯甲酰脲衍生物能够结合并中和促生存的Bcl-2蛋白。还描述了在治疗和/或预防与细胞死亡失调相关的疾病或症状中使用苯甲酰脲衍生物。
• Inhibitors of aspartyl protease
  申请人：Vertex Pharmaceuticals Incorporated.

  公开号：US20040122000A1

  公开（公告）日：2004-06-24

  The present invention relates to a novel class of sulfonamides which are aspartyl protease inhibitors. In one embodiment, this invention relates to a novel class of HIV aspartyl protease inhibitors characterized by specific structural and physicochemical features. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting HIV-1 and HIV-2 protease activity and consequently, may be advantageously used as anti-viral agents against the HIV-1 and HIV-2 viruses. This invention also relates to methods for inhibiting the activity of HIV aspartyl protease using the compounds of this invention and methods for screening compounds for anti-HIV activity.

  本发明涉及一类新型磺胺类化合物，其为天冬氨酸蛋白酶抑制剂。在一个实施例中，本发明涉及一类新型HIV天冬氨酸蛋白酶抑制剂，其具有特定的结构和理化特征。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制HIV-1和HIV-2蛋白酶活性，因此，可以有利地用作抗HIV-1和HIV-2病毒的抗病毒剂。本发明还涉及使用本发明的化合物抑制HIV天冬氨酸蛋白酶活性的方法以及筛选具有抗HIV活性的化合物的方法。